story of the week
Gemcitabine and Oxaliplatin Plus Glofitamab or Rituximab for Relapsed or Refractory DLBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
Lancet 2024 Nov 16;404(10466)1940-1954, JS Abramson, M Ku, M Hertzberg, HQ Huang, CP Fox, H Zhang, DH Yoon, WS Kim, H Abdulhaq, W Townsend, C Herbaux, JM Zaucha, QY Zhang, H Chang, Y Liu, CY Cheah, H Ghesquieres, S Simko, V Orellana-Noia, R Ta, J Relf, M Dixon, M Kallemeijn, E Mulvihill, H Huang, L Lundberg, GP GregoryFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.